On December 31, Gloronghui reported that Jimin Health (603222.SH) announced the completion of its non-public stock issuance fundraising project "Annual Production of 850 Million Safe Syringes and Safe Injection Needles Technical Transformation Project," and the project has been completed. The office of its wholly owned subsidiary, Jumin Biotechnology Co., Ltd. (referred to as "Jumin Biotechnology"), has been relocated from "No. 1888 Hu-Hang Highway, Fengxian District, Shanghai" to "No. 398 Renjie South Road, Fengxian, Shanghai." The House Rental Agreement between Jumin Biotechnology and its related party, Shanghai Shuangge Industry Co., Ltd. (referred to as "Shanghai Shuangge Industry"), has also been terminated.

Considering: 1. On October 10, 2014, the related party Shanghai Shuangge Industry and actual controller Li Xianyu family promised regarding Jumin Biotechnology's lease of property from Shanghai Shuangge Industry: "If relocation due to government compulsory expropriation causes Jumin Biotechnology to move from the leased premises, we will voluntarily bear all relocation costs and compensate for the losses caused to Jumin Biotechnology due to the relocation; we will fully assist and support Jumin Biotechnology in obtaining substitute land use rights and constructing new production and office premises through the public listing transfer process, and bear the expenses incurred during this period. If Jumin Biotechnology fails to obtain substitute land through the public listing transfer process within 12 months, we will immediately seek suitable standard factory buildings for Jumin Biotechnology to purchase or lease, compensate for all direct and indirect losses caused, and are willing to bear the liability for breach of contract under the leasing agreement according to the relevant provisions of the leasing agreement." 2. On September 30, 2022, in the House Rental Agreement signed by Shanghai Shuangge Industry and Jumin Biotechnology, Shanghai Shuangge Industry also promised: "If the relevant government departments expropriate, requisition, or recover the land use rights of the leased premises or make any demands to terminate the leasing matter, the party A promises to compensate for the direct economic losses caused to party B's production and operation. "

According to the asset evaluation report No. 0734 (2024) issued by Shanghai Zhonghua Asset Appraisal Co., Ltd. regarding the losses involving building decoration, equipment, and handling costs due to the early termination of the lease, Jumin Biotechnology's losses related to the early termination of the lease for the premises originally located at No. 1888 Hu-Hang Highway amounted to a total assessed value of 7,986,800 yuan as of the assessment benchmark date of October 31, 2024. After negotiation, the above losses will be fully compensated by Shanghai Shuangge Industry to Jumin Biotechnology.